With In vivo rodent models of carcinogen-induced mammary carcinomas have demonstrated the ability of Adiol to stimulate tumour growth, even in the presence of aromatase inhibitors, confirming that this hormone does not need to be further aromatized to reveal its estrogenic effects [6]. This evidence concerns the gene CYP19A1 and neoplasm.